J Clin Pharmacol
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Loi, C.
Right arrow Articles by Sedman, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Loi, C.
Right arrow Articles by Sedman, A.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Articles

Lack of effect of type II diabetes on the pharmacokinetics of troglitazone in a multiple-dose study

CM Loi, EJ Randinitis, AB Vassos, DJ Kazierad, Koup JR, and AJ Sedman

Twelve patients with type II diabetes and 12 age-, weight-, and gender-matched healthy subjects participated in a study comparing the pharmacokinetics of troglitazone, metabolite 1 (sulfate conjugate), and metabolite 3 (quinone) after oral administration of 400 mg of troglitazone every morning for 15 days. Serial plasma samples collected after the dose on days 1 and 15 were analyzed for troglitazone, metabolite 1, and metabolite 3 using a validated HPLC method. Steady state plasma concentrations of troglitazone and its metabolites were achieved by the fifth day of troglitazone administration in both groups. Mean day 15 Cmax, tmax, AUC0-24, and Cl/F values of troglitazone were 1.54 micrograms/mL, 3.25 hours, 15.6 micrograms.hr/mL, and 461 mL/min, respectively, in patients with type II diabetes. Corresponding parameter values were 1.42 micrograms/mL, 2.63 hours, 12.5 micrograms.hr/mL, and 558 mL/min, respectively, in healthy subjects. Elimination t1/2 was approximately 24 hours in both groups. Mean day 15 pharmacokinetic parameter values for metabolite 1 and metabolite 3 were similar in the two groups. Ratio of AUC of metabolite 1 to troglitazone was 6.2 and 6.7, respectively, in patients and in healthy subjects. Ratio of AUC of metabolite 3 to troglitazone was 1.1 in both groups. Thus, steady-state pharmacokinetics and disposition of troglitazone and its metabolites in patients with type II diabetes were similar to those in healthy subjects.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 International Journal of ToxicologyHome page
G. Vansant, P. Pezzoli, R. Saiz, A. Birch, C. Duffy, F. Ferre, and J. Monforte
Gene Expression Analysis of Troglitazone Reveals Its Impact on Multiple Pathways in Cell Culture: A Case for In Vitro Platforms Combined with Gene Expression Analysis for Early (Idiosyncratic) Toxicity Screening
International Journal of Toxicology, March 1, 2006; 25(2): 85 - 94.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Katoh, T. Matsui, H. Okumura, M. Nakajima, M. Nishimura, S. Naito, C. Tateno, K. Yoshizato, and T. Yokoi
EXPRESSION OF HUMAN PHASE II ENZYMES IN CHIMERIC MICE WITH HUMANIZED LIVER
Drug Metab. Dispos., September 1, 2005; 33(9): 1333 - 1340.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
T. Nozawa, S. Sugiura, M. Nakajima, A. Goto, T. Yokoi, J.-I. Nezu, A. Tsuji, and I. Tamai
INVOLVEMENT OF ORGANIC ANION TRANSPORTING POLYPEPTIDES IN THE TRANSPORT OF TROGLITAZONE SULFATE: IMPLICATIONS FOR UNDERSTANDING TROGLITAZONE HEPATOTOXICITY
Drug Metab. Dispos., March 1, 2004; 32(3): 291 - 294.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
W. Honma, M. Shimada, H. Sasano, S. Ozawa, M. Miyata, K. Nagata, T. Ikeda, and Y. Yamazoe
Phenol Sulfotransferase, ST1A3, as the Main Enzyme Catalyzing Sulfation of Troglitazone in Human Liver
Drug Metab. Dispos., August 1, 2002; 30(8): 944 - 949.
[Abstract] [Full Text] [PDF]

Home page
 Toxicol SciHome page
J. R. Herman, L. A. Dethloff, E. J. McGuire, R. F. Parker, K. M. Walsh, A. W. Gough, H. Masuda, and F. A. de la Iglesia
Rodent Carcinogenicity with the Thiazolidinedione Antidiabetic Agent Troglitazone
Toxicol. Sci., July 1, 2002; 68(1): 226 - 236.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
Y. Yamamoto, H. Yamazaki, T. Ikeda, T. Watanabe, H. Iwabuchi, M. Nakajima, and T. Yokoi
Formation of a Novel Quinone Epoxide Metabolite of Troglitazone with Cytotoxic to HepG2 Cells
Drug Metab. Dispos., February 1, 2002; 30(2): 155 - 160.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
V. E. Kostrubsky, J. F. Sinclair, V. Ramachandran, R. Venkataramanan, Y. H. Wen, E. Kindt, V. Galchev, K. Rose, M. Sinz, and S. C. Strom
The Role of Conjugation in Hepatotoxicity of Troglitazone in Human and Porcine Hepatocyte Cultures
Drug Metab. Dispos., October 1, 2000; 28(10): 1192 - 1197.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
R. E. Law, S. Goetze, X.-P. Xi, S. Jackson, Y. Kawano, L. Demer, M. C. Fishbein, W. P. Meehan, and W. A. Hsueh
Expression and Function of PPAR{gamma} in Rat and Human Vascular Smooth Muscle Cells
Circulation, March 21, 2000; 101(11): 1311 - 1318.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1997 by the American College of Clinical Pharmacology